- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04781309
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
A Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Background:
Progressive multifocal leukoencephalopathy (PML) is a brain infection. It is caused by a virus. PML can happen in people with a weakened immune system. PML is associated with cognitive and visual impairment as well as motor and speech disturbances. There is no treatment for PML. Researchers want to see if a new drug can help.
Objective:
To see if the drug NT-I7 can help increase lymphocyte numbers, which may help control PML infection.
Eligibility:
Adults ages 18 and older with PML who are enrolled in Protocol #13-N-0017.
Design:
Participants will be screened under Protocol #13-N-0017.
Participants will have a 7-day inpatient stay, outpatient visits, and follow-up phone calls.
Participants will have a medical history and physical exam. They will give urine samples. Blood will be drawn from an arm vein or through an intravenous (IV) catheter.
Participants will get up to 3 doses of NT-I7. It will be given by injection into the muscle.
Participants will have lumbar punctures ( spinal taps ). A thin needle will be inserted into the spinal canal in the lower back. Cerebrospinal fluid will be removed. X-ray may be used to guide the procedure.
Participants will have magnetic resonance imaging (MRI) of the brain. The MRI scanner is a metal cylinder surrounded by a magnetic field. During MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get gadolinium, a contrast agent, through an IV catheter.
Participation will last for 12 to 19 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Description:
This protocol will test whether NT-I7 is a viable strategy for promoting immune reconstitution in lymphopenic patients with PML. Twelve adults with PML and lymphopenia (CD4 or CD8 T cell count of less than or equal to 200 cells/dL) from all causes will complete this pilot study. Patients will be observed as inpatient for the first 7 days following any experimental drug dosing. To follow, patients will return to NIH for a second 7-day inpatient stay by Day 21, and then for scheduled outpatient visits at NIH at month 2, 3, 6, 9 and 12 following any drug dosing. Follow up phone calls will be conducted at month 4, 5, 7 and 8. Patients may be eligible for a second dose of NT-I7 at higher dose if target ALC (1000/microliter) not reached, or at same dose if initial response is adequate but not sustained, for a maximum of 3 doses. The primary outcome measure is change in absolute lymphocyte counts (ALC). Secondary outcomes include safety and tolerability. Exploratory clinical, radiological, and laboratory measures will be obtained to investigate mechanism of action of NT-I7 and for biomarker development.
Objectives:
Primary Objective: To determine the kinetics and magnitude of effect of NT-I7 on absolute lymphocyte counts in patients with PML and underlying lymphopenia from various causes, in order to inform appropriate design of a future study.
Secondary Objectives: (1) To assess safety and tolerability of NT-I7. (2) To determine kinetics and magnitude of effect of NT-I7 on lymphocyte subsets. (3) To investigate effect of NT-I7 on PML disease course. (4) To investigate mechanism of action of NT-I7.
Endpoints:
Primary Endpoint: Change in absolute lymphocyte counts (ALC) over 6 months.
Secondary Endpoints: (1) Adverse event tables. (2) Change in lymphocyte subset counts, including CD4, CD8 and CD19 positive cells (3) Change in standardized disability rating scales, PML lesion extension by brain MRI, viral quantification in CSF and survival. (4) Exploratory serological and CSF measures to investigate immune response to JCV and mechanism of action of NT-I7.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Irene CM Cortese, M.D.
- Phone Number: (301) 496-9175
- Email: corteseir@ninds.nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY8664111010 800-411-1222
- Email: prpl@cc.nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
- Adults (18 years of age or older)
- Definite or Probable PML (2013 AAN Consensus Diagnostic Criteria)
- CD4 and/or CD8 lymphopenia less than or equal to 200 cells/dL from any cause that is not readily reversible within one month
- Enrolled in 13-N-0017
- Ability to provide own consent at study entry
- Ability to travel to NIH for study visits
- Willingness to comply with all study procedures
- If able to become pregnant or to father a child, patient must agree to commit to the use of a reliable/accepted method of birth control (i.e. hormonal contraception (birth control pills, injected hormones, vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or surgical sterilization (hysterectomy, tubal ligation, or vasectomy) for the duration of the study
EXCLUSION CRITERIA:
- Age < 18 years of age
- Ongoing treatment with immune-suppressive medications (exception: topical steroid use and all forms of systemic steroids with durations less than 2 weeks)
- Concurrent treatment with experimental therapies for PML that would interfere with or confound assessment of study outcomes
- History of underlying autoimmune disease involving the CNS
- Contraindication to any study procedures that would compromise ability to safely monitor the patient
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with study participation; or not in the best interest of the subject to participate, in the opinion of the treating investigator
- Women who are pregnant or breastfeeding
- Unwilling to have coded samples and/or data saved or used in other studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NT-I7
480 microgram/kg IM (initial dose)
|
NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc).
NT-I6 has a molecular weight of 104 kD.
The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the longitudinal change in absolute lymphocyte count over 6 months following study drug administration
Time Frame: over 6months following study drug administration
|
determine the kinetics and magnitude of effect of NT-I7 on absolute lymphocyte counts (ALC) in patients with PML and underlying lymphopenia from various causes, in order to inform appropriate design of a future study
|
over 6months following study drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: at each study timepoint
|
assessed by the occurrence of treatment-related adverse events.
These adverse events will be tabulated separately by timepoint to identify any trends in the data and will be described using number and percent.
|
at each study timepoint
|
Change in lymphocyte subsets, including CD4, CD8, and CD19 positive cells
Time Frame: at each study timepoint
|
These values will be investigated first descriptively at each timepoint using mean and SD or median and IQR, and then graphically.
Key comparisons of interest will include baseline to Month 3 and baseline to Month 6.
|
at each study timepoint
|
Disease course
Time Frame: at each study timepoint
|
These endpoints include quantification of JCV DNA in CSF and blood, change in Modified Rankin Scale score, change in Karnofsky Performance Scale score, change in PML lesion extension, change in pattern of contrast enhancement by brain MRI and survival.
Key comparisons of interest will include baseline to Month 3 and baseline to Month 6.
Here, the goal is to provide some initial proof of principle that the disease course is being impacted in a measurable way, particularly beyond Month 3.
|
at each study timepoint
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Irene CM Cortese, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Virus Diseases
- Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Demyelinating Diseases
- Hematologic Diseases
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- DNA Virus Infections
- Leukopenia
- Leukocyte Disorders
- Slow Virus Diseases
- Encephalitis
- Polyomavirus Infections
- Neuroinflammatory Diseases
- Lymphopenia
- Leukoencephalopathy, Progressive Multifocal
- Leukoencephalopathies
Other Study ID Numbers
- 10000126
- 000126-N
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progressive Multifocal Leukoencephalopathy
-
Fondation Ophtalmologique Adolphe de RothschildCompletedAIDS | Progressive Multifocal Leucoencephalopathy (PML)
-
BiogenTerminatedProgressive Multifocal LeukoencephalopathyUnited States, Germany
-
Cellevolve Bio IncNot yet recruitingProgressive Multifocal Leukoencephalopathy
-
First Affiliated Hospital of Zhejiang UniversityUnknownProgressive Multifocal Leukoencephalopathy | AIDSChina
-
National Institute of Neurological Disorders and...CompletedProgressive Multifocal LeukoencephalopathyUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompletedProgressive Multifocal Leukoencephalopathy
-
BiogenElan PharmaceuticalsTerminatedProgressive Multifocal LeukoencephalopathyUnited States, Brazil, Italy, Spain, Germany
-
University Hospital, ToulouseRecruitingProgressive Multifocal LeukoencephalopathyFrance
-
BiogenCompletedProgressive Multifocal LeukoencephalopathyUnited States
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; UpjohnCompletedHIV Infections | Leukoencephalopathy, Progressive MultifocalUnited States
Clinical Trials on NT-I7
-
PT Kalbe Genexine BiologicsGenexine, Inc.Recruiting
-
Genexine, Inc.Terminated
-
NeoImmuneTechNational Institute of Allergy and Infectious Diseases (NIAID); University of...Terminated
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Cancer Immunotherapy Trials Network (CITN)TerminatedHIV Infection | Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
Hyunseok Kang, MDNeoImmuneTechRecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell CarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); NeoImmuneTechTerminatedMalignant Glioma | LymphopeniaUnited States
-
National Cancer Institute (NCI)NeoImmuneTechWithdrawnBreast Carcinoma | Bladder Carcinoma | Colorectal AdenocarcinomaUnited States
-
Genexine, Inc.CompletedLocally Advanced or Metastatic Solid TumorsKorea, Republic of
-
Seoul National University HospitalUnknown
-
NeoImmuneTechRoche Pharma AGActive, not recruitingCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung CarcinomaUnited States